Geode Capital Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-32,476
| Closed | -$101K | – | 4534 |
|
|
2020
Q4 | $101K | Hold |
32,476
| – | – | ﹤0.01% | 4060 |
|
|
2020
Q3 | $100K | Hold |
32,476
| – | – | ﹤0.01% | 3907 |
|
|
2020
Q2 | $151K | Hold |
32,476
| – | – | ﹤0.01% | 3745 |
|
|
2020
Q1 | $167K | Buy |
32,476
+3
| +0% | +$22 | ﹤0.01% | 3608 |
|
|
2019
Q4 | $162K | Hold |
32,473
| – | – | ﹤0.01% | 3870 |
|
|
2019
Q3 | $256K | Hold |
32,473
| – | – | ﹤0.01% | 3691 |
|
|
2019
Q2 | $235K | Buy |
32,473
+1,749
| +6% | +$12.8K | ﹤0.01% | 3748 |
|
|
2019
Q1 | $245K | Buy |
30,724
+17,152
| +126% | +$161K | ﹤0.01% | 3673 |
|
|
2018
Q4 | $108K | Hold |
13,572
| – | – | ﹤0.01% | 3840 |
|
|
2018
Q3 | $209K | Hold |
13,572
| – | – | ﹤0.01% | 3760 |
|
|
2018
Q2 | $120K | Buy |
13,572
+5,072
| +60% | +$45K | ﹤0.01% | 3838 |
|
|
2018
Q1 | $75K | Sell |
8,500
-38
| -0.4% | -$391 | ﹤0.01% | 3897 |
|
|
2017
Q4 | $87K | Hold |
8,538
| – | – | ﹤0.01% | 3848 |
|
|
2017
Q3 | $132K | Buy |
8,538
+5,883
| +222% | +$69.5K | ﹤0.01% | 3767 |
|
|
2017
Q2 | $23K | Buy |
+2,655
| New | +$52K | ﹤0.01% | 4036 |
|
|
2016
Q4 | – | Sell |
-238
| Closed | -$3K | – | 4061 |
|
|
2016
Q3 | $3K | Buy |
238
+1
| +0.4% | +$28 | ﹤0.01% | 4026 |
|
|
2016
Q2 | $7K | Hold |
237
| – | – | ﹤0.01% | 4056 |
|
|
2016
Q1 | $5K | Sell |
237
-1
| -0.4% | -$27 | ﹤0.01% | 4096 |
|
|
2015
Q4 | $11K | Buy |
238
+1
| +0.4% | +$111 | ﹤0.01% | 4118 |
|
|
2015
Q3 | $42K | Buy |
237
+1
| +0.4% | +$197 | ﹤0.01% | 4026 |
|
|
2015
Q2 | $33K | Hold |
236
| – | – | ﹤0.01% | 3906 |
|
|
2015
Q1 | $31K | Buy |
236
+2
| +0.9% | +$327 | ﹤0.01% | 3901 |
|
|
2014
Q4 | $41K | Buy |
234
+1
| +0.4% | +$178 | ﹤0.01% | 3903 |
|
|
2014
Q3 | $55K | Buy |
233
+1
| +0.4% | +$334 | ﹤0.01% | 3828 |
|
|
2014
Q2 | $101K | Sell |
232
-1
| -0.4% | -$461 | ﹤0.01% | 3694 |
|
|
2014
Q1 | $106K | Buy |
233
+2
| +0.9% | +$1.04K | ﹤0.01% | 3649 |
|
|
2013
Q4 | $111K | Hold |
231
| – | – | ﹤0.01% | 3577 |
|
|
2013
Q3 | $111K | Buy |
231
+1
| +0.4% | +$479 | ﹤0.01% | 3473 |
|
|
2013
Q2 | $108K | Buy |
+230
| New | +$104K | ﹤0.01% | 3415 |
|
Other funds holding IDXG
Geode Capital Management's IDXG Position: Q1 2021 in Review
Geode Capital Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2021, closing a stake of 32,476 shares — an estimated $101K sold.
Geode Capital Management first reported a position in IDXG in Q2 2013 and held it in 29 quarters. The position peaked at $256K in Q3 2019. 3 funds tracked by Wall St. Rank hold IDXG as of Q1 2021.
- Geode Capital Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
- Geode Capital Management sold 32,476 Interpace Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $101K.
- Geode Capital Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 29 quarters.
- Geode Capital Management's Interpace Biosciences, Inc. Common Stock position peaked at $256K in Q3 2019.
- 3 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2021.
Based on Geode Capital Management's 13F filing for Q1 2021, filed 12 May 2021.